deaths (OS)

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus trastuzumab
trastuzumab emtansine vs. trastuzumab 1 certainty unassessable-28%
versus trastuzumab plus endocrine therapy
trastuzumab emtansine vs. trastuzumab plus endocrine therapy 1 -
trastuzumab emtasine plus endocrine therapy vs. trastuzumab plus endocrine therapy 1 -